Garabet, Lamya Ghanima, Waleed Monceyron Jonassen, Christine Skov, Vibe Holst, René Mowinckel, Marie-Christine Hans, C Hasselbalc Torben, A Kruse Thomassen, Mads Liebman, Howard
...
Published in
Platelets
Thrombopoietin-receptor-agonists (TPO-RA) are effective treatments of immune thrombocytopenia (ITP). Previous long-term TPO-RA clinical trials have shown that thrombotic events occurred in 6% of TPO-RA-treated ITP patients. To explore the increased risk of thrombosis, the effects of TPO-RA on markers of coagulation and P-selectin were studied. The ...
Tanous, Osama Steinberg Shemer, Orna Yacobovich, Joanne Zoldan, Meira Horovitz, Yoseph Yaniv, Isaac Rabizadeh, Esther Tamary, Hannah Nakav, Sigal Lahav, Judith
...
Published in
Platelets
Platelet function disorders (PFDs) are a common cause of mild bleeding tendency. However, they cannot be recognized by standard screening studies. The gold standard test for PFD is platelet aggregation, performed by light transmission aggregometry (LTA). A newer and less validated method is the closure time (CT), performed by the platelet function ...
Leunissen, Tesse C Wisman, Peter Paul van Holten, Thijs C de Groot, Philip G Korporaal, Suzanne J Koekman, Arnold C Moll, Frans L Teraa, Martin Verhaar, Marianne C de Borst, Gert Jan
...
Published in
Platelets
Patients on P2Y12 inhibitors may still develop thrombosis or bleeding complications. Tailored antiplatelet therapy, based on platelet reactivity testing, might reduce these complications. Several tests have been used, but failed to show a benefit of tailored antiplatelet therapy. This could be due to the narrowness of current platelet reactivity te...
Peng, Fenfen Li, Zhijian Yi, Chunyan Guo, Qunying Yang, Rui Long, Haibo Huang, Fengxian Yu, Xueqing Yang, Xiao
Published in
Platelets
Prior studies have shown that the levels of some platelet (PLT) indices were associated with mortality in patients undergoing hemodialysis. We aimed to investigate whether the changes in PLT indices associated with mortality in patients on peritoneal dialysis (PD). A single-center, retrospective observational cohort study was conducted in incident ...
Kapur, Rick Aslam, Rukhsana Kim, Michael Guo, Li Ni, Heyu Segel, George B Semple, John W
Published in
Platelets
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by low platelet counts. First-line treatment includes intravenous immunoglobulin (IVIg), however, its working mechanism remains incompletely understood. We investigated splenic and thymic dendritic cell (DC) subsets upon IVIg treatment in a well-characterized active muri...
Espitia, O Ternisien, C Agard, C Boisseau, P Denis, C V Fouassier, M
Published in
Platelets
We present here a 63-year old woman with a long history of immune thrombocytopenia. She was hospitalized for a traumatic intracranial hemorrhage with thrombocytopenia. Following inefficient treatment of four platelet transfusions, immunoglobulins, and corticosteroids, we initiated treatment with a thrombopoietin (TPO) receptor agonist (eltrombopag ...
Tsai, Wen-Chung Yu, Tung-Yang Lin, Li-Ping Lin, Miao-Sui Wu, Yi-Cheng Liao, Chih-Hao Pang, Jong-Hwei S
Published in
Platelets
Platelet rich plasma (PRP) contains various cytokines and growth factors which may be beneficial to the healing process of injured muscle. The purpose of this study is to investigate the effect and molecular mechanism of PRP releasate on proliferation of skeletal muscle cells. Skeletal muscle cells intrinsic to Sprague-Dawley rats were treated with...
Pellerin, David Lortie, Audrey Corbin, François
Published in
Platelets
Fragile X Syndrome (FXS) is the most common inherited form of intellectual disability and the leading monogenic cause of autism spectrum disorders (ASD). Despite a large number of therapeutics developed in past years, there is currently no targeted treatment approved for FXS. In fact, translation of the positive and very promising preclinical findi...
Landry, Sébastien Tanguay, Jean-François Lordkipanidzé, Marie
Published in
Platelets
Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is currently the standard of care for the prevention of ischemic events in patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Several studies have shown that not all patients benefit from the treatment to the same degree and demonstrated that...
Mohammad, Moman A Andell, Pontus Koul, Sasha James, Stefan Scherstén, Fredrik Götberg, Matthias Erlinge, David
Published in
Platelets
Patients pretreated with ticagrelor with less than 1 hour from percutaneous coronary intervention (PCI) or receiving ticagrelor in cath lab were prospectively included and received cangrelor. Cangrelor was infused for 2 hours and platelet function was assessed as P2Y12 reactivity units (PRU) with the VerifyNow P2Y12 function assay before start of i...
